25-HYDROXYVITAMIN D AND MATRIX METALLOPROTEINASES-2, -9 LEVEL IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA AND PSEUDOEXFOILIATIVE GLAUCOMA/SYNDROME

I.S. Beletskaya1, T.L. Karonova1,2, S.Yu. Astachov1

1 FSBEI HE Academician I.P. Pavlov First St Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation, Saint Petersburg, Russia;
2 Federal Almazov North-West Medical Research Center, Saint Petersburg, Russia


Received: 28.12.2016
Accepted: 22.02.2017

Aim. To determine serum 25(OH)D and plasma MMP-2 and MMP-9 levels in patients with primary open-angle glaucoma (POAG), pseudoexfoliation glaucoma (PEG), and pseudoexfoliation syndrome (PES) — to assess potential associations between vitamin D status and the above mentioned diseases. Methods. We included 238 patients (105 males and 133 females) aged from 55 to 75 years. One hundred twenty two patients had PEG, 46 patients had POAG, 32 had PES. 38 subjects were healthy, and were considered as the control group. Cases with clinically significant systemic diseases and concomitant eye diseases were excluded, if there was a confirmed pathogenic impact of vitamin D and MMP. The serum 25(OH)D level was investigated by immunochemiluminescence method, plasma MMP-2 and MMP-9 levels — by ELISA. Results. Serum 25(OH)D level was between 4.6 and 82.25 nM/l (mean 41.7 nM/l), so most participants showed vitamin D deficiency. It was shown that mean serum 25(OH)D level in patients with PEG, POAG and PES was similar (39.3 ± 1.2, 38.8 ± 2.1 and 40.51 ± 2.4 nM/l, p > 0.05), but it was lower than those in the control group (52.7 ± 2.1 nM/l, p < 0.01). Plasma MMP-2 concentration was the same in all study groups. Plasma MMP-9 level was higher in POAG and PES patients (48.23 ± 3.26 and 54.01 ± 3.57 ng/ml) than in the control group (32.60 ± 2.34 ng/ml, p < 0.001) and in patients with PEG (40.86 ± 3.60 ng/ml, p < 0.05). We found positive correlations between MMP-2 and MMP-9 levels in patients with PEG (r = 0.48, p = 0.001) and patients with PES (r = 0.32, p = 0.02). The correlation analysis showed also a negative relation between 25(OH)D and MMP-9 (r = −0.32, p = 0.02), as well as MMP-2 (r = −0.33, p = 0.02) in patients with POAG. Summary. Study results confirmed a potential role of vitamin D in apoptosis regulation and tissue remodeling in patients with PEG and PES. Hence, vitamin D deficiency can be considered as a risk factor for glaucoma development.

Keywords: open angle glaucoma; pseudoexfoliative glaucoma; pseudoexfoliation syndrome; matrix metalloproteinases; vitamin D.

УРОВЕНЬ 25-ГИДРОКСИВИТАМИНА D И МАТРИКСНЫХ МЕТАЛЛОПРОТЕИНАЗ-2 И -9 У БОЛЬНЫХ ПЕРВИЧНОЙ ОТКРЫТОУГОЛЬНОЙ ГЛАУКОМОЙ И ПСЕВДОЭКСФОЛИАТИВНОЙ ГЛАУКОМОЙ/СИНДРОМОМ

И.С. Белецкая1, Т.Л. Каронова1,2, С.Ю. Астахов1

1 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава России, Санкт-Петербург;
2 ФГБУ «Северо-Западный федеральный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России, Санкт-Петербург

Для цитирования: Офтальмологические ведомости. – 2017. – Т. 10. – № 1. – С. 10–16
Статья принята к печати: 22.02.2017

Цель работы: определить уровень 25-гидроксивитамина D в сыворотке крови у больных первичной открытогоугольной глаукомой (ПОУГ),
expression of genes responsible for the synthesis to regulate intraocular pressure (IP) through gene interactions. The 1,25-dihydroxyvitamin D (calcitriol) was shown to downregulate the expression of genes involved in the synthesis of carbonic anhydrase 1, angiotensin-converting enzyme, and aquaporin 1. Besides, calcitriol is likely to regulate the expression of genes involved in the synthesis of some cytoskeleton and extracellular matrix components, such as fibronectin 1 and alpha actin [17]. Calcitriol can upregulate the expression of genes encoding matrix metalloproteinases (MMP) and simultaneously decrease the activity of their tissue inhibitors involved in the regulation of the trabecular meshwork metabolism [17].

So far, very few studies have attempted to investigate the association between glaucoma and its severity, and the level of vitamin D [12, 25]. Despite the high prevalence of both vitamin D deficiency and glaucoma, there are no Russian studies devoted to this problem.

The objective of this study is to assess serum levels of 25-hydroxyvitamin D and classic markers of apoptosis and tissue remodeling, like MMPs, and to clarify their impact on the development of various forms of glaucoma.

**MATERIALS AND METHODS**

We enrolled 238 individuals (105 males and 133 females; aged 55–75 y) in this study, after they signed an informed consent. We excluded patients
who had at least one of the following conditions: diabetes mellitus; cancer; autoimmune disorders; severe comorbidity; therapy with corticosteroids, immunosuppressants, or vitamin D; acute circulatory disorders of the central retinal artery/vein; ocular trauma; corneal disorders; wet form of age-related macular degeneration.

In all patients, diagnosis was confirmed by an ophthalmologic examination that included autorefractometry, visual acuity assessment, Maklakov’s applanation tonometry, biomicrophthalmoscopy, automated perimetry, and Heidelberg Retinal Tomography II. Patients were examined at the out-patient department, and at the Department of Ophthalmology of the Pavlov First Saint Petersburg State Medical University.

We measured the serum 25(OH)D levels by immunochemiluminescence method using the Architect i2000SR System (Abbott Laboratories, USA). We followed the recommendations of the Russian Association of Endocrinologists (2015) in assessing Vitamin D deficiency: serum 25(OH)D levels of 75 nmol/L (normal); 50–75 nmol/L (insufficient); 50 nmol/L (deficient) [6]. We used ELISA to measure the concentrations of serum MMP-2 and MMP-9 using the Quantikine Total MMP-2 Immunoassay (R&D Systems, Inc., USA & Canada) and Human MMP-9 Platinum ELISA Kit (eBioscience, USA), respectively.

Statistical analysis was performed using the SPSS17.0RU for Windows. We calculated the rates and mean values with standard deviations. Pearson $\chi^2$ test was used to compare categorical variables. Continuous variables were compared using ANOVA. We calculated the Pearson’s correlation coefficient to assess the correlation between the variables.

Results

Mean age of the participants was 66.7 ± 0.3 y. Out of 238 individuals tested, 196 were diagnosed with pseudoexfoliation glaucoma (PEG)/POAG/PES, and the remaining 38 individuals comprised the control group (mean age 65.2 ± 0.8 y). All patients were divided into three groups: group 1—patients with PEG ($n = 122$; mean age 67.4 ± 0.4 y), group 2—patients with POAG ($n = 46$; mean age 65.5 ± 0.9 y), and group 3—patients with PES without glaucoma ($n = 32$; mean age 67.4 ± 1.0 y). Patients in all the groups were matched for gender and age.

The serum 25(OH)D level in patients and controls varied between 4.6 and 82.3 nmol/L (mean level was 41.7 nmol/L); most of the study participants were vitamin D deficient. Our results were similar to the results of the study that evaluated the prevalence of vitamin D deficiency in the Northwest region of the Russian Federation [5]. The level of 25(OH)D did not significantly differ among patients with PEG, POAG, and PES (39.3 ± 1.2 nmol/L, 38.8 ± 2.1 nmol/L, and 40.51 ± 2.4 nmol/L, respectively; $p > 0.05$), but it was lower than in controls (52.7 ± 2.1 nmol/L; $p < 0.01$). None of the patients with PEG, POAG, or PES had normal serum levels of 25(OH)D. The number of patients with vitamin D deficiency did not vary across the experimental groups and comprised 87.4%, 80.0%, and 78.1% in the first, second, and third group respectively. Only three (8.1%) participants from the control group had normal serum 25(OH)D levels (over 75 nmol/L); the number of individuals with vitamin D deficiency was lower among the controls (62.2 %, $p < 0.05$) compared to the patients with PEG/POAG/PES.

We found no significant difference in the levels of MMP-2 across the groups: it was 248.3 ± 18.5, 249.9 ± 15.8, 224.7 ± 11.3, and 224.7 ± 11.3 ng/mL, in patients with PEG, POAG, PES, and in controls, respectively ($p > 0.05$).

The serum MMP-9 level was significantly higher in patients with POAG and PES (48.2 ± 3.3 and 54.0 ± 3.6 ng/mL, respectively) when compared to either the controls (32.6 ± 2.3 ng/mL, $p < 0.001$) or patients with PEG (40.9 ± 3.6 ng/mL, $p < 0.05$ and $p < 0.01$, respectively).

We also analyzed the concentrations of MMP-2 and MMP-9 depending on the stage of glaucoma. We divided glaucoma patients into three groups depending on the disease stage: early (stage 1), advanced (stage 2), and severe (stage 3) (in accordance with the National Guideline on Glaucoma) [4]. The results of the analysis are shown in the Table 1.

Serum levels of 25(OH)D, MMP-2, and MMP-9 did not significantly differ in patients with different stages of POAG and PEG ($p > 0.05$). Then, we merged the stage-2 and stage-3 to form a single group (AS), and compared against the early stage glaucoma (ESG). Individuals with both ES- and AS-POAG were found to have higher levels of MMP-9 (47.8 ± 3.6 ng/mL and 48.6 ± 5.5 ng/mL, respectively) compared to patients with advanced/severe PEG (38.7 ± 4.6 ng/mL; $p < 0.01$ and $p < 0.05$ for ESG vs. PEG and AS vs. PEG, respectively).

We found a positive correlation between the levels of MMP-2 and MMP-9 in patients with PEG ($r = 0.48$, $p = 0.001$) and POAG ($r = 0.43$, $p = 0.003$) and a negative correlation between
The serum 25(OH)D level, plasma MMP-2 and MMP-9 levels in patients with different pseudoexfoliation and primary open-angle glaucoma severity

Table 1
Уровень 25(OH)D в сыворотке крови и концентрация матриксных металлопротеиназ (MMP-2, MMP-9) в плазме крови у больных с различной степенью тяжести псевдоэксфолиативной и первичной открытогоугольной глаукомы

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Stage 1</th>
<th>Stage 2</th>
<th>Stage 3</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEG (n = 122)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>67.2 ± 0.6</td>
<td>67.3 ± 0.9</td>
<td>67.6 ± 0.8</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>25(OH)D, nmol/L</td>
<td>38.8 ± 2.1</td>
<td>42.6 ± 2.0</td>
<td>37.8 ± 2.2</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>MMP-2, ng/mL</td>
<td>233.1 ± 41.9</td>
<td>276.0 ± 38.4</td>
<td>246.0 ± 21.6</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>MMP-9, ng/mL</td>
<td>44.9 ± 5.7</td>
<td>33.2 ± 5.2</td>
<td>40.6 ± 5.9</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>PES (n = 32)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>67.5 ± 1.2</td>
<td>63.5 ± 2.3</td>
<td>67.2 ± 1.9</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>25(OH)D, nmol/L</td>
<td>38.1 ± 2.9</td>
<td>40.5 ± 3.1</td>
<td>38.8 ± 5.1</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>MMP-2, ng/mL</td>
<td>250.9 ± 21.7</td>
<td>236.2 ± 17.2</td>
<td>259.7 ± 40.9</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>MMP-9, ng/mL</td>
<td>47.8 ± 3.6</td>
<td>43.7 ± 7.0</td>
<td>52.3 ± 8.2</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Control group (n = 38)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>65.5 ± 1.2</td>
<td>63.5 ± 2.3</td>
<td>67.2 ± 1.9</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>25(OH)D, nmol/L</td>
<td>39.3 ± 1.2</td>
<td>40.5 ± 2.4</td>
<td>52.7 ± 2.1</td>
<td>p &lt; 0.01</td>
</tr>
<tr>
<td>MMP-2, ng/mL</td>
<td>248.3 ± 18.5</td>
<td>234.4 ± 23.9</td>
<td>224.7 ± 11.3</td>
<td>p &gt; 0.05</td>
</tr>
<tr>
<td>MMP-9, ng/mL</td>
<td>40.9 ± 3.6</td>
<td>54.0 ± 3.6</td>
<td>32.6 ± 2.3</td>
<td>p &lt; 0.01</td>
</tr>
</tbody>
</table>

POAG—primary open-angle glaucoma, PEG—pseudoexfoliation glaucoma, 25(OH)D—25-hydroxyvitamin D, MMP-2—matrix metalloproteinase-2, MMP-9—matrix metalloproteinase-9

The levels of 25(OH)D and MMP-9 (r = -0.32, p = 0.02), 25(OH)D and MMP-2 (r = -0.33, p = 0.02) in patients with POAG.

Levels of 25(OH)D, MMP-2, and MMP-9 were comparable in patients with PES, PEG, and controls (Table 2).

Participants in the control group had the highest level of serum 25(OH)D (p < 0.01) compared to those with PEG and PES. The highest level of MMP-9 was observed in patients with PES (which differed significantly from the control and PEG groups), whereas the level of MMP-2 was approximately equal in all groups (Table 2).

**DISCUSSION**

The results of our study confirmed high prevalence of vitamin D deficiency in patients with different types of glaucoma. The serum 25(OH)D level does not depend on the stage of glaucoma, a finding that correlates with the results obtained by Goncalves et al. (2015) [12]. Glaucoma is a chronic progressive optic neuropathy with multiple factors (immunological disorders, ischemia, oxidative stress, and apoptosis) potentially contributing to its development. Vitamin D is known to have pleiotropic effects, including its ability to regulate cell differentiation, inflammatory and immune...
processes, and apoptosis. Moreover, some eye disorders, including glaucoma, were found to be associated with certain geographic regions and the level of insolation [1, 3, 9]. Some authors believe that vitamin D deficiency can activate several pathogenic mechanisms of glaucoma [17, 25]. MMPs are known to play an important role in the development of glaucomatous optic neuropathy [7, 11, 13, 15, 20, 21]. Our findings indicate higher levels of MMP-9 in patients with POAG and PES compared to controls. Furthermore, patients with both early and advanced POAG, as well as patients with PES, had higher concentrations of MMP-9 compared to patients with severe PEG ($p < 0.01, p < 0.05$, and $p < 0.01$, respectively). Patients with PEG tended to have higher levels of MMP-9 than controls, but the difference was not statistically significant. Our data confirm the earlier published results suggesting high serum concentrations of MMP-9 in patients with POAG [7, 11]. At the same time, serum level of MMP-2 appeared to be approximately equal in individuals with POAG, PEG, and PES, and did not depend on the disease severity. A negative correlation between the serum 25(OH)D level and concentrations of MMP-2 and MMP-9 possibly indicates elevated levels of apoptosis markers associated with vitamin D deficiency, but these changes were found only in patients with POAG. Our findings provide support to the idea of vitamin D playing a regulatory role in patients with systemic disorders [18, 23].

PES is a well-known risk factor for PEG, which is characterized by a more aggressive course, and is poorly amenable to medical and surgical correction [2, 3]. Within this study, patients with PES had lower serum 25(OH)D levels compared to controls ($p < 0.01$), but was not significantly different from those with PEG and POAG, whereas the concentration of MMP-9 occurred to be the highest in participants with PES. Moreover, we found no difference in the level of MMP-9 between patients with PES and early stage PEG. Our results suggest that patients with PES/early stage PEG, along with vitamin D deficiency, are likely to have an active apoptotic process, and intensive compensatory remodeling of connective tissues and neuroglia, in the posterior pole and optic disc.

**CONCLUSION**

Our study revealed high prevalence of vitamin D deficiency in patients with POAG, PEG, and PES. A correlation between the level of vitamin D and MMPs (MMP-2 and MMP-9) was found only in patients with POAG. This may indicate the involvement of vitamin D in the regulation of apoptosis and tissue remodeling in patients with POAG. Besides, it allows considering vitamin D deficiency as a risk factor for glaucoma.

**REFERENCES**


**Information about the authors**

Inessa S Beletskaya — MD. Ophthalmology Department, FS-BEI HE “Academician I.P. Pavlov First St Petersburg State Medical University” of the Ministry of Healthcare of the Russia, Saint Petersburg, Russia. E-mail: glaziki@list.ru.

Inessa Stanislavovna Belyatskaya — врач-офтальмолог. ФГБОУ ВО «ПСПбГМУ им. И.П. Павлова» Минздрава России, Санкт-Петербург. E-mail: glaziki@list.ru.
<table>
<thead>
<tr>
<th>Information about the authors</th>
<th>Сведения об авторах</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tatiana L. Karonova</strong> — MD, PhD, Professor. Department of Internal Diseases No 2 with the Course of Endocrinology, Cardiology and Functional Diagnostics with Clinic No 1. FSBEI HE “Academician I.P. Pavlov First St Petersburg State Medical University” of the Ministry of Healthcare of Russia; DMSs, Head, Scientific Research Laboratory of Clinical Endocrinology of Endocrinology Institute, Federal Almazov North-West Medical Research Center, Saint Petersburg, Russia. E-mail: <a href="mailto:karonova@mail.ru">karonova@mail.ru</a>.</td>
<td><strong>Татьяна Леонидовна Каронова</strong> — д-р мед. наук, профессор кафедры терапии факультетской с курсом эндокринологии и клиникой. ФГБОУ ВО «ПСПбГМУ им. И.П. Павлова» Минздрава России, Санкт-Петербург; заведующая НИЛ Клинической эндокринологии Института эндокринологии. ФГБУ «СЗФМИЦ им. В.А. Алмазова» Минздрава России, Санкт-Петербург. E-mail: <a href="mailto:karonova@mail.ru">karonova@mail.ru</a>.</td>
</tr>
<tr>
<td><strong>Sergey Yu. Astakhov</strong> — MD, PhD, professor, head of the department. Ophthalmology Department. FSBEI HE “Academician I.P. Pavlov First St Petersburg State Medical University” of the Ministry of Healthcare of Russia, Saint Petersburg, Russia. E-mail: <a href="mailto:astakhov73@mail.ru">astakhov73@mail.ru</a>.</td>
<td><strong>Сергей Юрьевич Астахов</strong> — д-р мед. наук, профессор, заведующий кафедрой офтальмологии. ФГБОУ ВО «ПСПбГМУ им. И.П. Павлова» Минздрава России, Санкт-Петербург. E-mail: <a href="mailto:astakhov73@mail.ru">astakhov73@mail.ru</a>.</td>
</tr>
</tbody>
</table>